Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study

Hepatology Research

Volumn 37, Issue 7, 2007, Pages 490-497

  Nomura, Hideyuki ^a   Kashiwagi, Yoichiro ^a   Hirano, Ryouko ^a   Tanimoto, Hironori ^a   Tsutsumi, Nobuo ^a   Higashi, Masashi ^b   Ishibashi, Hiromi ^c  

^a Shin Kokura Hospital   (Japan)

^b National Hospital Organization   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

Author keywords

Aged patients; Alpha fetoprotein; Chronic hepatitis C; Interferon; Long term treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ALPHA INTERFERON; PEGINTERFERON; RIBAVIRIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; GENOTYPE; GERIATRIC PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; LOW DRUG DOSE; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; VIRUS LOAD;

EID: 34249889291     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00073.x     Document Type: Article

References (27)

1. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
2. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
3. Nomura H, Tanimoto H, Kajiwara E et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004; 19: 1312-17.
4. Hiramatsu N, Oze T, Tsuda N et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 2006; 35: 185-9.
5. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006; 43: 1177-86.
6. Yaginuma R, Ikejima K, Okumura K et al. Hepatic steatosis is a predictor of poor response to interferon α-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C. Hepatol Res 2006; 35: 19-25.
7. Hamada H, Yatsuhashi H, Yano K et al. Impact of aging on the development of hepatocellular carcinoma in patients with post-transfusion chronic hepatitis C. Cancer 2002; 15: 331-9.
8. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
9. Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
10. Murashima S, Tanaka M, Haramaki M et al. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci 2006; 51: 808-12.
11. Nagaki M, Imose M, Naiki T et al. Prospective study on early virologic response to treatment with interferon alpha-2b plus ribavirin in patients with chronic hepatitis C genotype 1b. Hepatol Res 2005; 33: 285-91.
12. Yuki N, Hayashi N, Kasahara A et al. Pretreatment viral load and response to prolonged interferon-alpha course for chronic hepatitis C. J Hepatol 1995; 22: 457-63.
13. Lau JY, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
14. Shiratori Y, Kato N, Yokosuka O et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997; 113: 558-66.
15. Nomura H, Kimura Y, Tada H et al. Predictive factors of a response to interferon therapy in chronic hepatitis C. J Clin Gastroenterol 1996; 23: 185-90.
16. Nomura H, Tsuchiya Y, Maruyama T et al. The effects of a high dose, short course of interferon on hepatitis C. J Gastroenterol Hepatol 1999; 14: 85-9.
17. Okanoue T, Itoh Y, Kirishima T et al. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. Hepatol Res 2002; 23: 62-77.
18. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-81.
19. Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.
20. Yamashita F, Tanaka M, Satomura S et al. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996; 111: 996-1001.
21. Aoyagi Y, Mita Y, Suda T et al. The fucosylation index of serum alpha-fetoprotein as useful prognostic factor in patients with hepatocellular carcinoma in special reference to chronological changes. Hepatol Res 2002; 23: 287.
22. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004; 127: S113-19.
23. Watanabe A, Shiota T, Hayashi S et al. Serum alpha-fetoprotein in fulminant hepatitis and hepatic regeneration following partial hepatectomy. Biochem Med 1984; 32: 132-7.
24. Arase Y, Ikeda K, Tsubota A et al. Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load. Hepatol Res 2003; 25: 364-70.
25. Arase Y, Suzuki F, Tsubota A et al. Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load. Intervirology 2004; 47: 19-25.
26. Nomura H, Tanimoto H, Sou S et al. Pilot study of prolonged interferon-alpha retreatment in chronic hepatitis C patients with genotype 1b. Hepatol Res 2003; 27: 266-71.
27. Nomura H, Kashiwagi Y, Nakashima H et al. Efficacy of prolonged treatment following combination with ribavirin and interferon for chronic hepatitis type C: A pilot study. Hepatol Res 2005; 31: 211-16.